Here's what we'll cover
Here's what we'll cover
Semaglutide, the active ingredient in Ozempic and Wegovy, already has proven benefits for blood sugar, weight, the heart, and the kidneys. A study published in Nature on September 2, 2026 adds a striking new finding: in old female mice, starting semaglutide late in life slowed several signs of aging and extended lifespan.
It is a genuinely interesting result. It is also a mouse study, and the gap between mice and people is wide. Here is what the researchers found and how to read it.
What the Study Found
The research, led by Danica Chen at the University of California, Berkeley and funded by the National Institute on Aging, was published as Feng and colleagues in Nature and summarized by the National Institutes of Health.
| Study detail | Finding |
|---|---|
| Animals | Female mice only |
| Age at start | 20 months, roughly equivalent to older adulthood in people |
| Median lifespan | About 834 days with semaglutide vs about 742 days untreated, a gain of about 92 days |
| Function | Better muscle function, motor coordination, memory, and exploratory behavior |
| Biology | Less age related inflammation and cellular senescence, more new neurons in the hippocampus |
The lifespan figures come from News Medical's summary of the paper. A gain of about 92 days is roughly 12% of median lifespan in these mice.
Is It Just Eating Less?
This was the central question, because eating fewer calories is one of the most reliable ways to extend lifespan in lab animals, and semaglutide reduced the mice's food intake by about 24%.
To test it, the researchers compared semaglutide with a diet that cut calories by the same amount. Both groups held up well, but only the semaglutide mice improved above their starting level in spatial memory, exploration, and blood sugar control. Metabolic rate dropped with calorie restriction but stayed largely stable with semaglutide. Chen said these differences point to the possibility that GLP-1 drugs tap into a pathway independent of calorie restriction, according to the NIH.
That is a possibility, not a proven mechanism. The study did not identify the pathway.
Why Inflammation Matters
Chronic low grade inflammation, sometimes called inflammaging, contributes to heart disease, cognitive decline, and frailty. Gene expression analysis in the treated mice showed fewer inflammatory signals and other hallmarks of aging. That fits with human trial data showing semaglutide lowers inflammatory markers and reduces cardiovascular events.
What This Study Does Not Tell Us
- Whether semaglutide extends lifespan or healthspan in people
- Whether the effect occurs in male mice, since only females were studied
- What dose or duration would matter for aging in humans
- Whether tirzepatide or other GLP-1 drugs have similar effects
- Whether benefits would appear in people without obesity or diabetes
The NIH notes the findings do not imply that similar results could be achieved immediately in humans. Many treatments that extend lifespan in mice have not translated to people.
How This Fits With Human Evidence
The mouse finding sits alongside a strong and growing body of human trial data, plus one important negative result.
| Condition | Evidence in people | Drug |
|---|---|---|
| Heart attack and stroke | 20% fewer major events in the SELECT trial | Semaglutide |
| Chronic kidney disease | 24% lower risk of serious kidney outcomes in the FLOW trial | Semaglutide |
| Obstructive sleep apnea | FDA approved after the SURMOUNT OSA trials | Tirzepatide |
| Fatty liver disease (MASH) | FDA approved for MASH with liver scarring in 2025 | Semaglutide |
| Early Alzheimer's disease | No slowing of progression in the EVOKE trials | Semaglutide |
| Aging and lifespan | Mouse data only | Semaglutide |
The heart data come from SELECT and the kidney data from FLOW. Tirzepatide's sleep apnea approval followed the SURMOUNT OSA trials. The Alzheimer's result is a useful reminder: in November 2025, two large trials found semaglutide did not slow early Alzheimer's disease, according to BioSpace, despite promising animal and observational data.
What About Tirzepatide?
Mounjaro and Zepbound contain tirzepatide, which acts on both GIP and GLP-1 receptors. It has not yet been tested in a comparable aging study, so there is no evidence either way.
Should You Start a GLP-1 to Slow Aging?
No. There is no approved use of semaglutide for aging, and the side effects, including nausea, gallbladder problems, and muscle loss during weight loss, are real. Starting a GLP-1 still depends on approved reasons such as obesity, type 2 diabetes, heart disease, kidney disease, or sleep apnea. If you already take semaglutide for one of those reasons, this study is encouraging but does not change your dose or plan.
No waiting list. No insurance needed.
Frequently Asked Questions
Does semaglutide slow aging?
In a 2026 Nature study, semaglutide slowed several signs of aging and extended median lifespan by about 92 days in old female mice. Whether it slows aging in people is unknown.
How much did semaglutide extend lifespan in mice?
Median lifespan rose from about 742 days to about 834 days in mice treated from 20 months of age, roughly a 12% increase.
Was the effect just from eating less?
Not entirely. Compared with a diet that cut calories by the same 24%, semaglutide mice improved more in memory, exploration, and blood sugar control. The pathway behind this has not been identified.
Were male mice studied?
No. The study used female mice only, so it is unknown whether males would respond the same way.
Should I take Ozempic or Wegovy to live longer?
No. Semaglutide is not approved for aging, and human evidence is lacking. Use it only for approved conditions under a doctor's care.
What proven benefits does semaglutide have beyond weight loss?
In human trials, semaglutide reduced major cardiovascular events by 20% in SELECT, lowered serious kidney outcomes in FLOW, and is approved for a form of fatty liver disease. It did not slow early Alzheimer's disease in the EVOKE trials.
The Bottom Line
A September 2026 Nature study found that semaglutide started late in life extended median lifespan by about 92 days in female mice and improved muscle, memory, and inflammation, with some benefits beyond calorie restriction alone. It is serious science from a respected lab.
It is also preliminary. Only female mice were studied, and the Alzheimer's trials show how often promising animal results fail in people. Use GLP-1 medications for the conditions they are proven to treat, and talk to your doctor before making any change. If you are exploring treatment, compare vetted telehealth providers and review current GLP-1 coupons and savings programs.